Weiss et al. [97] examined the synergistic effects of an active-targeted visudyne-mediated PDT with an anti-VEGF antibody (bevatizumab) and angiostatic tyrosine kinase inhibitors (TKIs, sunitinib, sorafenib, and axitinib) on two tumor models (A278 human ovarian carcinoma cells and HCT-116 human colorectal cancer cells). This evidence concerns the gene VEGFA and neoplasm.